GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:00072666 | Cervix | CC | Rho protein signal transduction | 35/2311 | 137/18723 | 1.77e-05 | 3.33e-04 | 35 |
GO:00465785 | Cervix | CC | regulation of Ras protein signal transduction | 44/2311 | 189/18723 | 2.05e-05 | 3.73e-04 | 44 |
GO:00512713 | Cervix | CC | negative regulation of cellular component movement | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
GO:00400133 | Cervix | CC | negative regulation of locomotion | 76/2311 | 391/18723 | 3.47e-05 | 5.60e-04 | 76 |
GO:20001463 | Cervix | CC | negative regulation of cell motility | 71/2311 | 359/18723 | 3.47e-05 | 5.60e-04 | 71 |
GO:00303363 | Cervix | CC | negative regulation of cell migration | 68/2311 | 344/18723 | 5.11e-05 | 7.70e-04 | 68 |
GO:00350235 | Cervix | CC | regulation of Rho protein signal transduction | 22/2311 | 86/18723 | 5.93e-04 | 5.60e-03 | 22 |
GO:00510585 | Cervix | CC | negative regulation of small GTPase mediated signal transduction | 15/2311 | 56/18723 | 2.60e-03 | 1.80e-02 | 15 |
GO:00350244 | Cervix | CC | negative regulation of Rho protein signal transduction | 8/2311 | 22/18723 | 3.43e-03 | 2.22e-02 | 8 |
GO:00465804 | Cervix | CC | negative regulation of Ras protein signal transduction | 13/2311 | 49/18723 | 5.34e-03 | 3.10e-02 | 13 |
GO:0007265 | Colorectum | AD | Ras protein signal transduction | 104/3918 | 337/18723 | 1.01e-05 | 2.35e-04 | 104 |
GO:0051056 | Colorectum | AD | regulation of small GTPase mediated signal transduction | 94/3918 | 302/18723 | 1.81e-05 | 3.76e-04 | 94 |
GO:0046578 | Colorectum | AD | regulation of Ras protein signal transduction | 56/3918 | 189/18723 | 2.85e-03 | 2.14e-02 | 56 |
GO:0051058 | Colorectum | AD | negative regulation of small GTPase mediated signal transduction | 21/3918 | 56/18723 | 3.26e-03 | 2.39e-02 | 21 |
GO:0007266 | Colorectum | AD | Rho protein signal transduction | 42/3918 | 137/18723 | 4.64e-03 | 3.16e-02 | 42 |
GO:00510562 | Colorectum | FAP | regulation of small GTPase mediated signal transduction | 78/2622 | 302/18723 | 3.25e-08 | 2.85e-06 | 78 |
GO:00072652 | Colorectum | FAP | Ras protein signal transduction | 80/2622 | 337/18723 | 9.61e-07 | 4.33e-05 | 80 |
GO:00465781 | Colorectum | FAP | regulation of Ras protein signal transduction | 47/2622 | 189/18723 | 4.67e-05 | 9.60e-04 | 47 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCAI | SNV | Missense_Mutation | | c.156T>G | p.His52Gln | p.H52Q | Q8N9R8 | protein_coding | deleterious_low_confidence(0) | benign(0.402) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCAI | SNV | Missense_Mutation | rs369558159 | c.901G>A | p.Ala301Thr | p.A301T | Q8N9R8 | protein_coding | deleterious(0.05) | possibly_damaging(0.561) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SCAI | SNV | Missense_Mutation | | c.400N>A | p.Val134Ile | p.V134I | Q8N9R8 | protein_coding | tolerated(0.59) | possibly_damaging(0.872) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SCAI | SNV | Missense_Mutation | | c.833G>A | p.Arg278His | p.R278H | Q8N9R8 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-E2-A15A-06 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
SCAI | SNV | Missense_Mutation | rs761266346 | c.1555N>T | p.Arg519Cys | p.R519C | Q8N9R8 | protein_coding | deleterious(0.03) | possibly_damaging(0.809) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SCAI | SNV | Missense_Mutation | | c.1453N>G | p.Pro485Ala | p.P485A | Q8N9R8 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SCAI | SNV | Missense_Mutation | | c.1060N>C | p.Glu354Gln | p.E354Q | Q8N9R8 | protein_coding | tolerated(0.17) | probably_damaging(0.986) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SCAI | SNV | Missense_Mutation | | c.1508A>G | p.Asn503Ser | p.N503S | Q8N9R8 | protein_coding | deleterious(0.03) | benign(0.199) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SCAI | SNV | Missense_Mutation | novel | c.892N>A | p.Leu298Met | p.L298M | Q8N9R8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SCAI | SNV | Missense_Mutation | novel | c.890N>T | p.Ser297Phe | p.S297F | Q8N9R8 | protein_coding | deleterious(0.02) | benign(0.023) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |